CustomNext-Cancer®
Use
CustomNext-Cancer can be used to identify patients with an inherited risk for hereditary cancers and is designed for unique clinical scenarios requiring flexibility. It allows healthcare providers to select from a list of genes to create a custom test tailored to their patient's specific clinical needs. This panel evaluates genes associated with cancer predisposition using next-generation sequencing, providing insights into potential inherited genetic risks for cancer development.
Special Instructions
Family variant testing is offered at no additional cost for all blood relatives of patients found to have a pathogenic variant after undergoing full single gene sequencing, multigene panel testing, or exome sequencing at Ambry Genetics. The offer is valid within 90 days of the original report date for U.S. residents only.
Limitations
The test excludes analysis of the MSH3 and PHOX2B polyalanine repeat regions. MITF is limited to the c.952G>A (p.E318K) variant. Gross deletion/duplication analysis is not performed for certain genes, and variants with low allele frequency or coverage are confirmed by Sanger sequencing. False negatives may occur if the variant is not covered by sequencing or underrepresents due to technical limitations.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Refer to ambrygen.com/specimen-requirements for details. Avoid samples from patients with active hematological disease or a history of allogenic bone marrow or stem cell transplant.
Causes for Rejection
Blood from patients with a history of allogenic bone marrow or peripheral stem cell transplant. Active hematological disease.